Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK2504
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical
- Modality
- Small Molecules
01
Overview
ZK2504 is an investigational small molecule therapeutic being developed by Lee's Pharmaceutical (also known as Lee's Pharm) for the treatment of solid tumors. Currently in the preclinical stage of development, ZK2504 is part of the company's oncology pipeline, which focuses on addressing various malignant conditions. While the specific biological target and mechanism of action for ZK2504 have not been publicly disclosed by the sponsor, the program is categorized as a targeted therapy within their antineoplastic portfolio. The asset is being advanced through early-stage studies to evaluate its safety and efficacy profile prior to potential clinical trial initiation.
Beyond the preview
Go deeper on ZK2504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK2504.